Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab Combination Therapy vs Ipilimumab Monotherapy in Patients With Advanced Unresectable Melanoma | Zendy

Abdulaali R. Almutairi | Zendy; Nimer S. Alkhatib | Zendy; Mok Oh | Zendy; Clara CurielLewandrowski | Zendy; Hani M. Babiker | Zendy; Lee D. Cranmer | Zendy; Ali McBride | Zendy; Ivo Abraham | Zendy

Open Access

Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab Combination Therapy vs Ipilimumab Monotherapy in Patients With Advanced Unresectable Melanoma

Author(s) -

Abdulaali R. Almutairi,

Nimer S. Alkhatib,

Mok Oh,

Clara CurielLewandrowski,

Hani M. Babiker,

Lee D. Cranmer,

Ali McBride,

Ivo Abraham

Publication year - 2018

Publication title -

jama dermatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.128

H-Index - 166

eISSN - 2168-6084

pISSN - 2168-6068

DOI - 10.1001/jamadermatol.2018.3958

Subject(s) - ipilimumab , medicine , oncology , quality of life (healthcare) , melanoma , immunotherapy , cancer , cancer research , nursing

A phase 2 trial comparing talimogene laherparepvec plus ipilimumab vs ipilimumab monotherapy in patients with advanced unresectable melanoma found no differential benefit in progression-free survival (PFS) but noted objective response rates (ORRs) of 38.8% (38 of 98 patients) vs 18.0% (18 of 100 patients), respectively.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research